Table 1.

Clinical characteristics and laboratory values of all patients evaluated

	HDV (n = 75)	HBV (n = 112)	HCV (n = 132)	P
Age at VCTE (years)	43.4 (11.5)	46.3 (14.0)	53.5 (10.7)	<0.0001
Gender   Male   Female	46 (61.3%) 29 (38.7%)	76 (67.9%) 36 (32.1%)	74 (56.1%) 58 (44.0%)	0.16
Race   White   Black   Asian   Other	26 (34.7%) 8 (8.0%) 41 (54.7%) 0 (0%)	27 (24.1%) 18 (16.1%) 66 (58.9%) 1 (0.8%)	67 (50.8%) 33 (25.0%) 22 (16.7%) 10 (7.5%)	<0.0001
Laboratory
ALP (IU/L)	84.7 (30.1)	69.4 (23.3)	76.0 (25.3)	0.002
AST (IU/L)	73.1 (64.3)	43.7 (43.2)	47.5 (37.3)	<0.0001
ALT (IU/L)	107.5 (124.0)	71.3 (89.3)	65.9 (60.0)	<0.0001
Total bilirubin (mg/dL)	0.77 (1.1)	0.71 (0.4)	0.67 (0.5)	0.42
GGT(IU/L)	59.3 (48.8)	41.3 (63.0)	77.3 (83.1)	<0.0001
Albumin (g/dL)	4.0 (0.44)	4.1 (0.4)	3.9 (0.4)	0.01
PT (seconds)	14.3 (1.4)	13.7 (1.0)	13.8 (0.9)	0.01
Platelet count (K/μL)	161.6 (76.0)	185.3 (57.3)	183.3 (70.7)	0.04
HBeAg positivity	11 (14.7%)	31 (27.7%)	N/A	0.03
HBeAb positivity	53 (70.7%)	63 (56.3%)	N/A	0.02
Nucleos(t)ide analog therapy	45 (60.0%)	49 (43.8%)	N/A	0.06
Histology	34 (45.3%)	112 (100%)	132 (100%)
HAI (0–18)	9.4 (2.4)	4.3 (3.3)	6.8 (2.9)	<0.0001
Ishak Fibrosis Stage (0–6)				<0.0001
0	1 (2.9%)	51 (45.5%)	31 (23.5%)
1	2 (5.9%)	24 (21.4%)	24 (18.2%)
2	8 (23.5%)	10 (8.9%)	23 (17.4%)
3	9 (26.5%)	10 (8.9%)	21 (15.9%)
4	4 (11.8%)	5 (4.5%)	9 (6.8%)
5	6 (17.7%)	3 (2.7%)	2 (1.5%)
6	4 (11.8%)	9 (8.0%)	22 (16.7%)
LSM (kPa)	13.3 (14.5)	7.2 (4.7)	11.1 (9.7)	<0.0001
Cirrhosis (Clinical + Histology)	18 (24.0%)	12 (10.7%)	24 (18.2%)	0.05

Values expressed as mean (standard deviation) or N (%) unless otherwise stated. HBV and HCV were compared to HDV for statistical analysis.

Abbreviations: ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; PT, prothrombin time; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; HAI, histology activity index; LSM, liver stiffness measurement; N/A, not applicable